INTRODUCTION TO THE Verve Therapeutics CLASS ACTION LAWSUIT

The Verve Therapeutics class action lawsuit seeks to represent purchasers or acquirers of Verve Therapeutics, Inc. (NASDAQ: VERV) publicly traded securities between August 9, 2022 and April 1, 2024, inclusive (the “Class Period”).  Captioned Oldroyd v. Verve Therapeutics, Inc., No. 24-cv-12218 (D. Mass.), the lawsuit charges Verve Therapeutics and certain of Verve Therapeutics’ top executives with violations of the Securities Exchange Act of 1934. 

If you have suffered losses in Verve Therapeutics stock and are interested in becoming the lead plaintiff in the Verve Therapeutics class action lawsuit or have any inquiries regarding your rights as a shareholder, please reach out to Verve Therapeutics Stock Loss Lawyer Timothy L. Miles at no cost.  You can contact him by calling 855/846-6529, sending an e-mail to [email protected], or filling out a contact form. 
​
Lead plaintiff motions in the Verve Therapeutics class action lawsuit must be filed with the court no later than October 28, 2024.

Verve Therapeutics class action lawsuit

​Verve Therapeutics, a clinical-stage genetic medicines company, is facing a class action lawsuit alleging misleading statements and omissions during its Heart-1 Phase 1b clinical trial of VERVE-101. Here are the key points in the Verve Therapeutics class action lawsuit:
Company overview:

  • Verve Therapeutics develops gene editing medicines for cardiovascular diseases
  • The company’s lead product, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver to reduce LDL cholesterol

Allegations of misconduct:

  • Failure to fully disclose circumstances under which the Heart-1 trial would be halted
  • Overstating the potential benefits of their proprietary lipid nanoparticles (LNP) delivery system
  • The class action lawsuit covers statements made during the Class Period (unspecified dates)
  • On April 2, 2024, Verve Therapeutics announced the halting of the Heart-1 clinical trial
  • Reason for trial halt: An adverse event in a participant who received a 0.45 mg/kg dose of VERVE-101
  • The company attributed the adverse event to their LNP delivery system

Stock market impact:

  • Following the announcement, Verve Therapeutics’ stock price plummeted by nearly 35%
  • This class action lawsuit highlights the risks associated with biotechnology investments and the importance of transparent communication in clinical trials

THE LEAD PLAINTIFF DEADLINE

​​Lead plaintiff motions for the Verve Therapeutics class action lawsuit must be filed with the court no later than October 28, 2024.​
When a securities class action is filed such as the Verve Therapeutics class action lawsuit:

  1. The person who files the first complaint is required to publish a notice announcing the filing.
  2. Anyone who wants to be lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published. 

THE LEAD PLAINTIFF PROCESS

​The Private Securities Litigation Reform Act of 1995 (PSLRA) permits any investor who purchased and suffered losses in Verve Therapeutics​​​ stock to seek appointment as lead plaintiff in the Verve Therapeutics class action lawsuit.

  • A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. 
  • A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit. 
  • An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. 

Verve Therapeutics

  1. ​Negotiating more competitive attorney fees and reducing litigation costs.
  2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
  3. Participating in mediation and settlement discussions.
  4. Having a voice in decision-making processes regarding the settlement.
  5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
  6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

THE RESPONSIBILITIES THE LEAD PLAINTIFF WILL HAVE

  1. Negotiating more competitive attorney fees and reducing litigation costs.
  2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
  3. Participating in mediation and settlement discussions.
  4. Having a voice in decision-making processes regarding the settlement.
  5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
  6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

ELIGIBILITY CRITERIA FOR LEAD PLAINTIFF APPOINTMENT

​To be eligible for appointment as the lead plaintiff in the Verve Therapeutics class action lawsuit, an investor must meet the following criteria:

  1. Securities Acquisition: The investor must have purchased or acquired Verve Therapeutics common stock during the Class Period, spanning August 9, 2022, and April 1, 2024.
  2. Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Verve Therapeutics​ and its executives.
  3. Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.

LEGAL REQUIREMENTS FOR PREVAILING IN THE Verve Therapeutics CLASS ACTION LAWSUIT

  1. ​Material Misrepresentation or Omission
  2. Scienter
  3. Connection to Securities Transaction
  4. Reliance
  5. Economic Loss
  6. Loss Causation

STAGES OF THE Verve Therapeutics CLASS ACTION LAWSUIT

  1. Consolidation and Lead Plaintiff Appointment
  2. Filing of Consolidated Complaint
  3. Motion to Dismiss
  4. Class Certification
  5. Discovery
  6. Settlement Negotiations and Mediation
  7. Summary Judgment Motions
  8. Trial
  9. Appeals